TriangleNCT02420795 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- every 3 months for 1 year, then every 6 months, up to 3 years
What was measured
Overall survival is the time in months from start of study treatment to date of death due to any cause.
Analysis population: Overall survival for each arm measured in months
Groups in this outcome
ONC201 125 mg
Patients receive Akt/ERK inhibitor ONC201 125 mg PO on day 1 of every cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ONC201 250 mg
Patients receive Akt/ERK inhibitor ONC201 250 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ONC201 625 mg
Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| ONC201 125 mg | 2 |
| ONC201 250 mg | 4 |
| ONC201 625 mg | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ONC201 125 mg | 29 | Not reported | 1 | 30 | Not reported |
| ONC201 250 mg | 15 | Not reported | 1 | 30 | Not reported |
| ONC201 625 mg | 24 | Not reported | 1 | 48 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1
- upper Limit
- 30
- value
- 29
- group Id
- OG001
- lower Limit
- 1
- upper Limit
- 30
- value
- 15
- group Id
- OG002
- lower Limit
- 1
- upper Limit
- 48
- value
- 24
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 5
- units
- Participants
- description
- Overall survival is the time in months from start of study treatment to date of death due to any cause.
- dispersion Type
- Full Range
- groups
- description
- Patients receive Akt/ERK inhibitor ONC201 125 mg PO on day 1 of every cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- ONC201 125 mg
- description
- Patients receive Akt/ERK inhibitor ONC201 250 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- ONC201 250 mg
- description
- Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG002
- title
- ONC201 625 mg
- param Type
- MEDIAN
- population Description
- Overall survival for each arm measured in months
- reporting Status
- POSTED
- time Frame
- every 3 months for 1 year, then every 6 months, up to 3 years
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice